SAFFRON #ESMO26 shows benefit in PFS/OS for adding MET targeted Rx into osi after 1L-PD.

IMO it’s an additional option rather than the new SOC here. Busy space with MET-active (MARIPOSA, CHRYSALIS) and agnostic (COMPEL, TROPION, Opti-TROP) options.

Re-biopsy is a limitation.